LOG IN
SIGN UP
MARKET
KPTI
KPTI
Karyopharm Therapeutics Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
6.38
+0.57
+9.81%
After Hours: 6.37 -0.01 -0.16% 18:51 05/27 EDT
OPEN
5.83
PREV CLOSE
5.81
HIGH
6.39
LOW
5.58
VOLUME
2.30M
TURNOVER
0
52 WEEK HIGH
14.73
52 WEEK LOW
4.420
MARKET CAP
506.69M
P/E (TTM)
-4.4888
1D
5D
1M
3M
1Y
5Y
Looking Into Karyopharm Therapeutics's Return On Capital Employed
Karyopharm Therapeutics (NASDAQ:KPTI) brought in sales totaling $47.67 million during Q1 according to data provided by Benzinga Pro. However, earnings decreased 206.92%, resulting in a loss of $41.40 million.
Benzinga · 1d ago
BRIEF-Karyopharm To Present New Selinexor Data At The 2022 American Society Of Clinical Oncology Annual Meeting
reuters.com · 2d ago
Karyopharm to Present New Selinexor Data at the 2022 American Society of Clinical Oncology Annual Meeting from June 3-June 7
Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced promising initial data from a Phase 1/2 study evaluating selinexor in combination
Benzinga · 2d ago
Karyopharm wins FDA’s Orphan Drug status for leading asset in myelofibrosis
The U.S. Food and Drug Administration (FDA) on Thursday granted its Orphan Drug Designation for Karyopharm Therapeutics (NASDAQ:KPTI) for the company’s leading product, selinexor in myelofibrosis. Selinexor is designed to selectively bind
Seekingalpha · 2d ago
Karyopharm begins dosing in late-stage study of selinexor combo therapy for multiple myeloma
Karyopharm Therapeutics (NASDAQ:KPTI) and the European Myeloma Network (EMN), a collaboration of centers for multiple myeloma in Europe and Australia, said the first patient was dosed in the collaborative EMN29/XPORT-MM-031 study.
Seekingalpha · 3d ago
The European Myeloma Network and Karyopharm Announce Dosing of First Patient in Collaborative EMN29/XPORT-MM-031 Study
The European Myeloma Network (EMN), an international collaborative network of expertise centers for multiple myeloma in Europe and Australia, and Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer...
PR Newswire · 3d ago
Karyopharm Therapeutics Doses First Patient in Clinical Study of Refractory Multiple Myeloma Treatment
MT Newswires · 3d ago
Karyopharm and Menarini Group Receive Positive CHMP Opinion for NEXPOVIO® (selinexor) for the Treatment of Patients with Refractory Multiple Myeloma
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, and the Menarini Group ("Menarini"), a privately-held, leading international pharmaceutical company, today announced that the European...
PR Newswire · 05/20 17:19
No Data
Learn about the latest financial forecast of KPTI. Analyze the recent business situations of Karyopharm Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 9 analysts
Buy
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
22.22%Strong Buy
22.22%Buy
55.56%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average KPTI stock price target is 12.38 with a high estimate of 21.00 and a low estimate of 5.00.
Current 6.38
EPS
Actual
Estimate
-0.48-0.220.050.31
Institutional Holdings
Institutions: 221
Institutional Holdings: 66.84M
% Owned: 84.17%
Shares Outstanding: 79.42M
TypeInstitutionsShares
Increased
51
3.49M
New
28
2.94M
Decreased
46
6.90M
Sold Out
15
484.52K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
President/Chief Executive Officer/Director
Richard Paulson
Chief Financial Officer/Senior Vice President/Treasurer
Michael Mason
Executive Vice President
Ran Frenkel
Senior Vice President/General Counsel/Secretary
Michael Mano
Senior Vice President/Director of Sales
Sohanya Cheng
Senior Vice President
Patricia Judson
Senior Vice President
Stephen Mitchener
Senior Vice President
Stuart Poulton
Chief Scientific Officer
Sharon Shacham
Lead Director/Independent Director
Barry Greene
Independent Director
Garen Bohlin
Independent Director
Peter Honig
Independent Director
Mansoor Mirza
Independent Director
Christy Oliger
Independent Director
Deepa Pakianathan
Independent Director
Chen Schor
No Data
No Data
About KPTI
Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (CRM1). Its lead compound, XPOVIO (selinexor), is marketed in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). NEXPOVIO (selinexor), the brand name for XPOVIO in Europe, in combination with dexamethasone to treat adult patients with multiple myeloma. It is also developing treatments for other diseases.
Webull offers kinds of Karyopharm Therapeutics Inc stock information, including NASDAQ:KPTI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KPTI stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading KPTI stock methods without spending real money on the virtual paper trading platform.